您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报（医学版） ›› 2015, Vol. 53 ›› Issue (2): 65-70.doi: 10.6040/j.issn.1671-7554.0.2014.119

• 临床医学 • 上一篇    下一篇

EZH2蛋白在卵巢上皮性肿瘤中的表达及其作用

陈静1, 李春艳1, 赵苗青2, 崔京睛1, 张娜3, 傅艺冰1   

  1. 1. 山东大学附属省立医院, 妇产科 山东 济南 250021;
    2. 山东大学附属省立医院, 病理科 山东 济南 250021;
    3. 山东大学附属省立医院, 手术麻醉科, 山东 济南 250021
  • 收稿日期:2014-03-08 发布日期:2015-02-10
  • 通讯作者: 傅艺冰. E-mail:fu_yibing@163.com E-mail:fu_yibing@163.com
  • 基金资助:
    国家自然科学基金(81172482);中国博士后科学基金( 2012M520201)

Expression of EZH2 protein and its role in ovarian epithelial tumor

CHEN Jing1, LI Chunyan1, ZHAO Miaoqing2, CUI Jingjing1, ZHANG Na3, FU Yibing1   

  1. 1. Department of Gynecology and Obstetrics, Provincial Hospital Affiliated to Shandong University, Jinan 250021, Shandong, China;
    2. Department of Pathology, Provincial Hospital Affiliated to Shandong University, Jinan 250021, Shandong, China;
    3. Department of Operation Anaesthesia, Provincial Hospital Affiliated to Shandong University, Jinan 250021, Shandong, China
  • Received:2014-03-08 Published:2015-02-10

PDF (PC)

195

摘要： 目的 观察EZH2在不同卵巢组织中的表达,探讨其在肿瘤发展中可能发挥的作用.方法 采用免疫组织化学染色检测15例正常卵巢组织、32例卵巢良性肿瘤、28例卵巢交界性肿瘤及50例卵巢癌中EZH2蛋白的表达,其中15例正常卵巢组织、23例卵巢良性肿瘤、23例交界性肿瘤及25例卵巢癌行RT-PCR检测.结果 ① EZH2蛋白在卵巢癌细胞核中的表达明显高于正常卵巢组织(P<0.01)、卵巢良性肿瘤(P<0.01)及交界性肿瘤(P<0.05),且与肿瘤的分级和分期具有相关性(P<0.01, P<0.05);② EZH2蛋白在卵巢肿瘤组织的细胞质中亦有表达,且良性肿瘤和交界性肿瘤中的表达高于卵巢癌(P均<0.05) ;③ EZH2蛋白在卵巢癌细胞核中的表达与Ki-67呈正相关性(r=0.40, P<0.01).结论 卵巢肿瘤组织细胞核及细胞质中均有EZH2蛋白的表达,且卵巢癌细胞核中EZH2蛋白的表达与肿瘤的分期及分级具有相关性,并参与细胞增殖.

关键词: Ki-67, EZH2蛋白, EZH2 mRNA, 卵巢肿瘤, 细胞质

Abstract: Objective To explore the expression of EZH2 protein in different epithelial ovarian tumors and its possible role in tumor development. Methods Immunohistochemistry was used to detect EZH2 protein expression in 15 normal ovarian tissues, 32 ovarian benign tumors, 28 ovarian borderline tumors and 50 primary epithelial ovarian cancers. Real-time quantitative PCR (RT-PCR) was used to detect EZH2 mRNA expression in 15 normal ovarian tissues, 23 ovarian benign tumors, 23 borderline tumors and 25 epithelial ovarian cancers. Results ① EZH2 expressed highly in nucleus in epithelial ovarian cancers compared with normal ovarian tissue (P<0.01), benign tumor (P<0.01) and borderline tumor (P<0.05). EZH2 expression was significantly correlated with grade and staging of tumor in epithelial ovarian cancers (P<0.01, P<0.05). ② EZH2 protein expressed in cytoplasm in ovarian tumor, and it expressed highly in benign ovarian tumor and borderline tumor compared with epithelial ovarian cancers (P<0.05). ③ The nuclear expression of EZH2 protein in epithelial ovarian cancers was positively correlated with Ki-67 (r=0.40, P<0.01). Conclusion EZH2 protein expresses in both nucleus and cytoplasm in ovarian tumors, and its elevated nuclear expression in epithelial ovarian cancers is associated with not only staging and grade of tumor, but also cell proliferation.

Key words: Ovarian cancer, Ki-67, EZH2 protein, EZH2 mRNA, Cytoplasm

中图分类号: 

  • R737.31
[1] Jemal A, Siegel R, Xu JQ, et al. Cancer statistics[J]. Cancer J Clin, 2010, 60(5): 277-300.
[2] 毛晓韵, 姚凡, 金锋. EZH2与乳腺癌发生发展的关系[J]. 中华肿瘤防治杂志, 2010, 17(2): 149-152. MAO Xiaoyun, YAO Fan, JIN Feng. Relationship between EZH2 gene and carcinogenesis and progress of breast cancer[J]. Chin J Cancer Prev Treat, 2010, 17(2): 149-152.
[3] Min J, Zaslavsky A, Fedele G, et al. An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-κB[J]. Nat Med, 2010, 16(3): 286-294.
[4] Moore HM, Gonzalez ME, Toy KA, et al. EZH2 inhibition decreases p38 signaling and suppresses breast cancer motility and metastasis[J]. Breast Cancer Research and Treatment, 2013, 138(3): 741-752.
[5] Chang CJ, Hung MC. The role of EZH2 in tumor progression[J]. Br J Cancer, 2012, 106(2): 243-247.
[6] 褚金曼, 杜咏梅, 骆树瑜, 等. EZH2和Ki-67蛋白在腺样囊性癌中的表达及其临床意义[J]. 中国肿瘤临床, 2014, 41(5): 311-314. CHU Jinman, DU Yongmei, LUO Shuyu, et al. Expression of EZH2 and Ki-67 in salivary adenoid cystic carcinoma and their clinical significance[J]. Chinese Journal of Clinical Oncology, 2014, 41(5): 311-314.
[7] Ren G, Baritaki S, Marathe H, et al. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer[J]. Cancer Research, 2012, 72(12): 3091-3104.
[8] Au SL, Wong CC, Lee JM, et al. Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis[J]. Hepatology, 2012, 56(2): 622-631.
[9] Crea F, Fornaro L, Bocci G, et al. EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis[J]. Cancer Metastasis Reviews, 2012, 31(3-4): 753-761.
[10] Xu L, Beckebaum S, Iacob S, et al. MicroRNA-101 inhibits human hepatocellular Carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity[J]. Journal of Hepatology, 2014, 60(3): 590-598.
[11] Fluge , Gravdal K, Carlsen E, et al. Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis[J]. Br J Cancer, 2009, 101(8): 1282-1289.
[12] Yon R. Linking JNK-STAT3-Akt signaling axis to EZH2 phosphorylation: A novel pathway of carcinogenesis[J]. Cell Cycle, 2013, 12(2): 202-203.
[13] Seward S, Semaan A, Qazi AM, et al. EZH2 blockade by RNA interference inhibits growth of ovarian cancer by facilitating re-expression of p21(waf1/cip1) and by inhibiting mutant p53[J]. Cancer Letters, 2013, 336(1): 53-60.
[14] Jaenisch R, Young R. Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming[J]. Cell, 2008, 132(4): 567-582.
[15] Su IH, Dobenecker MW, Dickinson E, et al. Polycomb group protein ezh2 controls actin polymerization and cell signaling[J]. Cell, 2005, 121(3): 425-436.
[16] Sauteur L, Krudewig A, Herwig L, et al. Cdh5/VE-cadherin Promotes Endothelial Cell Interface Elongation via Cortical Actin Polymerization during Angiogenic Sprouting[J]. Cell Rep, 2014, 9(2): 504-13.
[1] 王伟 王沂峰 张岭梅 林琼燕 黄菊. 人卵巢癌OVCAR3细胞系中侧群细胞的分离及其成瘤性、侵袭性的实验研究[J]. 山东大学学报(医学版), 2209, 47(6): 8-11.
[2] 张希英,翟春颜,李劲松,韩博. 中国尤文肉瘤患者EZH2蛋白表达与临床病理学参数及预后的关系[J]. 山东大学学报（医学版）, 2017, 55(2): 84-91.
[3] 赵路,矫俊,张腾,焦薪霖,崔保霞. 肝X受体在卵巢癌组织中的表达及T0901317在卵巢癌细胞系SKOV3中的作用[J]. 山东大学学报（医学版）, 2017, 55(1): 49-53.
[4] 肖俊超,蒋雯,南慧,王培荣. 重组腺病毒35型纤毛突蛋白增强西妥昔单抗的抗卵巢癌作用[J]. 山东大学学报（医学版）, 2016, 54(5): 1-5.
[5] 张春霞,邹存华,宋冬冬,余江. P38MAPK信号通路对卵巢癌中尿激酶型纤维蛋白酶原激活剂的影响[J]. 山东大学学报（医学版）, 2016, 54(2): 68-74.
[6] 崔勇, 张荣香, 王福立, 王国颖, 冯建林, 张海霞. BSD2000相控阵聚焦深部热疗联合TP方案化疗治疗晚期卵巢癌的临床效果[J]. 山东大学学报（医学版）, 2015, 53(7): 53-57.
[7] 吕树卿, 尉蔚, 张灿灿, 田永杰. HGF/PARP-1信号通路调控卵巢癌细胞侵袭转移的作用[J]. 山东大学学报（医学版）, 2015, 53(7): 1-7.
[8] 周静, 常晓天, 周婷, 崔莹莹, 张蓓, 荣风年. 沉默PADI4基因对卵巢癌细胞系OVCAR3的作用[J]. 山东大学学报（医学版）, 2015, 53(6): 48-53.
[9] 付伟1，高文娟2，张志勉1，曲迅2，赵玉霞3. 罗勒多糖对卵巢癌SKOV3细胞VEGF受体表达的调控作用及对其侵袭能力的影响[J]. 山东大学学报（医学版）, 2014, 52(5): 39-43.
[10] 周静, 郑亚冰, 闫莉, 常晓天, 赵珊, 荣风年. 雌激素及顺铂对卵巢癌细胞A2780PADI4的表达及其细胞增殖的影响[J]. 山东大学学报（医学版）, 2014, 52(12): 30-34.
[11] 贾宗洋,张向宁,靳艳慧,魏美玲. PD98059联合顺铂对卵巢癌细胞增殖的影响[J]. 山东大学学报(医学版), 2013, 51(2): 27-32.
[12] 解放，刘帅，刘征，牛志宏. NOV基因与Ki-67、VEGF、p27和COX-2在肾透明细胞癌中的相关性[J]. 山东大学学报(医学版), 2013, 51(10): 29-32.
[13] 姜昕1，郭文彬1，朱梅1，李巧1，江婷2，张烁1. 载紫杉醇PLGA微球在Skov3卵巢癌荷瘤小鼠体内的治疗效果[J]. 山东大学学报(医学版), 2013, 51(1): 33-36.
[14] 张艳霞1，章培军2，闫燕艳3，段爱旭4，李加善2，牛三强5. Ki-67、PCNA 和Survivin在胃肠道间质瘤组织中的表达[J]. 山东大学学报(医学版), 2013, 51(1): 67-70.
[15] 代军1，刘培淑1，马道新2，常新忠1，冯进波1，尹格平3. cyclinD1在卵巢癌裸鼠移植瘤组织中的表达及意义[J]. 山东大学学报(医学版), 2012, 50(6): 57-60.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发